Glycomic Therapeutics Market Report 2025

The glycomic therapeutics market size has grown rapidly in recent years. It will grow from $164.71 billion in 2024 to $190.03 billion in 2025 at a compound annual growth rate (CAGR) of 15.4%. The growth in the historic period can be attributed to increased awareness of glycan significance, rise in chronic diseases, drug development for rare diseases, collaborations in glycomics research.

The glycomic therapeutics market size is expected to see rapid growth in the next few years. It will grow to $361.09 billion in 2029 at a compound annual growth rate (CAGR) of 17.4%. The growth in the forecast period can be attributed to expanding knowledge of glycan biology, precision medicine approaches, rising interest in immunotherapy, increased funding for rare diseases research, emergence of glycan biomarkers. Major trends in the forecast period include expansion of glycomic applications in oncology, glycoengineering for enhanced therapeutic proteins, inclusion of glycomics in immuno-oncology, glycomics in rare and genetic disorders, regulatory considerations for glycomic drugs.

The rising prevalence of diabetes is anticipated to propel the growth of the glycomic therapeutics market. Diabetes is a chronic condition that impairs the body's ability to regulate blood sugar (glucose) levels. In individuals with diabetes, changes in glycans have been noted, which may lead to insulin resistance and other metabolic issues. Specific glycan patterns can act as biomarkers for diagnosing diabetes, forecasting its progression, and monitoring treatment responses. For example, in March 2022, the IDF Diabetes Atlas, a Belgium-based global resource that provides detailed data and insights on diabetes prevalence, projected that the global number of diabetes cases would rise from 643 million in 2030 to 783 million by 2045, representing an increase of 140 million cases. Thus, the growing prevalence of diabetes is driving the expansion of the glycomic therapeutics market.

The rising incidence of cancer is poised to drive the growth of the glycomic therapeutics market. Cancer, characterized by uncontrolled cell growth and spread, sees applications of glycomic therapeutics in treatment. These therapeutics target and modify specific sugar molecules on cell surfaces, influencing crucial cellular interactions, signaling pathways, and immune responses, with the goal of inhibiting tumor growth and enhancing the effectiveness of cancer therapies. For example, in 2023, the estimated number of new cases of liver cancer in females in the United States increased from 12,660 in 2022 to 13,230 in 2023, as reported by the American Cancer Society. Therefore, the increasing prevalence of cancer is a key factor driving the growth of the glycomic therapeutics market.

Product innovation stands out as a prominent trend gaining traction in the glycomic therapeutics market. Key players in the glycomic therapeutics sector are strategically investing in the development of cutting-edge technologies and innovative solutions to fortify their market position. For example, in April 2022, Glenmark Pharmaceuticals Limited, an Indian-based pharmaceutical company dedicated to discovering advanced therapies, introduced a novel fixed-dose combination (FDC) featuring a DPP4 inhibitor (Dipeptidyl Peptidase 4 inhibitor), Teneligliptin, with Pioglitazone. This innovative combination aims to enhance glycemic control and reduce insulin resistance in patients with type 2 diabetes.

Leading companies in the glycomic therapeutics sector are actively engaged in the creation of groundbreaking technological solutions, such as screening kits, to advance glycobiology research and exploration. A screening kit is a pre-packaged set of tools and materials designed for a preliminary test to detect the presence or absence of a specific substance, condition, or property. For instance, in July 2022, Vector Laboratories, a US-based provider of glycomic solutions, launched Glysite Scout Glycan screening kits. These kits, fully integrated for immunofluorescence, facilitate the detection of glycan expression in tissue sections, allowing researchers to profile and characterize complex glycans in biological systems and identify major surface glycan motifs in a sample.

In May 2022, Halozyme Therapeutics, a US-based biotechnology company, completed the acquisition of Antares Pharma Inc. for $960 million. This strategic move bolstered Halozyme's pipeline portfolio of novel treatments utilizing advanced drug delivery methods, enhancing safety, efficacy, convenience, tolerability, and patient comfort and adherence. Antares Pharma Inc. is a US-based pharmaceutical firm.

Major companies operating in the glycomic therapeutics market include F Hoffmann-La Roche Ltd., Bayer AG, Sanofi SA, Thermo Fisher Scientific Inc., GlaxoSmithKline plc, Merck KGaA, ICON plc, Agilent Technologies Inc., AMS Bio, Shimadzu Corporation, Waters Corporation, Bruker Corporation, BioMarin Pharmaceutical Inc., Bio Techne Corp., Promega Corporation, Halozyme Therapeutics Inc., Takara Bio Inc., Vector Laboratories, New England Biolabs Inc., Protalix Biotherapeutics Inc., Genovis AB, Ray Biotech Life Inc., IEC Group, Ludger Ltd, Z Biotech LLC, Alzheon Inc., GlycoMar Limited.

North America was the largest region in the glycomic therapeutics in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the glycomic therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the glycomic therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Glycomic therapeutics involves the application of glycomics-based approaches in the field of therapeutic development. The glycome, which constitutes the complete set of glycans in a cell or organism, plays a crucial role in understanding the intricate nature of biological systems and their implications for health and disease. Glycans are involved in diverse biological processes, including cell signaling, immune responses, and the development of diseases.

The primary types of glycomic therapeutics fall into two classes isolated and synthetic. Isolated glycomic therapy focuses on the study and analysis of glycans in isolation, delving into the structural and functional characterization of individual glycan molecules. Synthetic glycomic therapy involves the use of artificially created glycans or glycan-based molecules for diagnosing and treating various diseases or medical conditions. These therapies target different structures such as glycoproteins, sialic acid, proteoglycans, glycosaminoglycans, glycosylphosphatidylinositol (GPI)-anchored proteins, heparin-based glycans, glycosphingolipids, and others. The mode of action varies, including inhibiting neuraminidase, heparanase, selectins, blocking interactions between growth factors and heparan sulfate, and applications in erythropoietin and enzyme replacement therapy (ERT), tissue plasminogen activator, inhibiting glucosylceramide synthase, and targeting interleukins, interferons, among others. These therapies are employed for indications such as thrombosis and chemoprophylaxis, anemia, anti-adhesive and anti-inflammatory purposes, cataracts, Gaucher’s disease, MPS-1 and IV, cancer, Alzheimer's disease, influenza types A and B, and more.

The glycomic therapeutics market research report is one of a series of new reports that provides glycomic therapeutics market statistics, including glycomic therapeutics industry global market size, regional shares, competitors with a glycomic therapeutics market share, detailed glycomic therapeutics market segments, market trends and opportunities, and any further data you may need to thrive in the glycomic therapeutics industry. This glycomic therapeutics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The glycomic therapeutics market consists of sales of investigational glycomic therapeutics and therapeutic glycomic that target glycans or glycan-related pathways for the diagnosis and treatment of diseases. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.